vobarilizumab   Click here for help

GtoPdb Ligand ID: 8363

Synonyms: ALX-0061
Immunopharmacology Ligand
Compound class: Antibody
Comment: Vobarilizumab is an investigational bispecific peptide NanobodyTM which binds soluble IL-6R and human albumin (albumin binding being utilised as a half-life extension methodology). Design and production of ALX-0061 is described in patent US8748581 [2]. Vobarilizumab is being developed for the treatment of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Preclinical information is published in [6].
The exact NanobodyTM structure being used as ALX-0061 was not revealed in the covering patent [2], but has been disclosed in the INN submission. Annotated peptide sequences for this therapeutic are available from its IMGT/mAb-DB record.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]
2. Beirnaert EAA, Ververken CJN, Kolkman JA, Van Roy M. (2014)
Anti-IL-6R polypeptides and pharmaceutical compositions thereof.
Patent number: US8748581. Assignee: Ablynx N.V.. Priority date: 10/04/2009. Publication date: 10/06/2014.
3. Hirohata S, Kikuchi H. (2012)
Changes in biomarkers focused on differences in disease course or treatment in patients with neuro-Behçet's disease.
Intern Med, 51 (24): 3359-65. [PMID:23257520]
4. Kristiansen OP, Mandrup-Poulsen T. (2005)
Interleukin-6 and diabetes: the good, the bad, or the indifferent?.
Diabetes, 54 Suppl 2: S114-24. [PMID:16306329]
5. Tackey E, Lipsky PE, Illei GG. (2004)
Rationale for interleukin-6 blockade in systemic lupus erythematosus.
Lupus, 13 (5): 339-43. [PMID:15230289]
6. Van Roy M, Ververken C, Beirnaert E, Hoefman S, Kolkman J, Vierboom M, Breedveld E, 't Hart B, Poelmans S, Bontinck L et al.. (2015)
The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis.
Arthritis Res Ther, 17: 135. [PMID:25994180]